TR200103665T2 - Nöro ve -retino-koruyucu oftalmolojik ilaçlar - Google Patents

Nöro ve -retino-koruyucu oftalmolojik ilaçlar

Info

Publication number
TR200103665T2
TR200103665T2 TR2001/03665T TR200103665T TR200103665T2 TR 200103665 T2 TR200103665 T2 TR 200103665T2 TR 2001/03665 T TR2001/03665 T TR 2001/03665T TR 200103665 T TR200103665 T TR 200103665T TR 200103665 T2 TR200103665 T2 TR 200103665T2
Authority
TR
Turkey
Prior art keywords
ramiprilate
retino
neuro
protective
chorioretinopathy
Prior art date
Application number
TR2001/03665T
Other languages
English (en)
Inventor
Rekik Raouf
Original Assignee
Elyes, Ben, Mohamed, Raouf Rekik
Rekik Raouf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9915359A external-priority patent/FR2794975A1/fr
Application filed by Elyes, Ben, Mohamed, Raouf Rekik, Rekik Raouf filed Critical Elyes, Ben, Mohamed, Raouf Rekik
Publication of TR200103665T2 publication Critical patent/TR200103665T2/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Bulus, etken maddenin ramipril ya da ramiprilat ya da uygulandigi organizma içinde ramiprilat serbestleme kapasitesine sahip bir baska türevden olusan grup içinden seçildigi bir nöro-koruyucu ve retino-koruyucu ilaca iliskindir. Normal deneklerde görüs keskinligi ve görme alaninin korunmasi ve hatta iyilestirilmesinde kullanildigi gibi, vasküler bir faktörü olan oftalmoljik patolojilerin, özellikle de glokomatöz nöropatiler, ileri derece miyopta dejeneratif korioretinopati yasa bagli maküler dejenerasyon,seröz santral korioretinopati, retinada kalitsal distrofiler ve retinada ven tikanmasi gibi patolojilerin tedavisinde kullanilmaktadir. Pratik olarak görme fonksiyonunda (görüs keskinligi ve görme alani) her zaman iyilesme saglamaktadir.
TR2001/03665T 1999-06-16 2000-06-16 Nöro ve -retino-koruyucu oftalmolojik ilaçlar TR200103665T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TN99122 1999-06-16
FR9915359A FR2794975A1 (fr) 1999-06-16 1999-12-06 Medicaments opthalmologiques neuro et retino-protecteurs

Publications (1)

Publication Number Publication Date
TR200103665T2 true TR200103665T2 (tr) 2002-10-21

Family

ID=26235177

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03665T TR200103665T2 (tr) 1999-06-16 2000-06-16 Nöro ve -retino-koruyucu oftalmolojik ilaçlar

Country Status (20)

Country Link
US (1) US7049340B1 (tr)
EP (1) EP1185255B1 (tr)
JP (1) JP2003501461A (tr)
AT (1) ATE424819T1 (tr)
AU (1) AU6449000A (tr)
BR (1) BR0011714A (tr)
CA (1) CA2376909A1 (tr)
CZ (1) CZ20014516A3 (tr)
DE (1) DE60041765D1 (tr)
DK (1) DK1185255T3 (tr)
ES (1) ES2324200T3 (tr)
HU (1) HUP0201478A3 (tr)
MA (1) MA26798A1 (tr)
MX (1) MXPA01012907A (tr)
NO (1) NO20016088L (tr)
PL (1) PL352365A1 (tr)
SI (1) SI1185255T1 (tr)
SK (1) SK18772001A3 (tr)
TR (1) TR200103665T2 (tr)
WO (1) WO2000076499A2 (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826276A1 (fr) * 2001-06-20 2002-12-27 Raouf Rekik Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2377531A2 (en) * 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
TNSN08110A1 (en) * 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
RU2471454C2 (ru) * 2010-12-14 2013-01-10 Валерий Викторович Педдер Способ лечения дистрофических заболеваний сетчатки глаза
EP2866805A1 (en) * 2012-06-29 2015-05-06 Raouf Rekik Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114333B1 (en) 1982-12-27 1990-08-29 Schering Corporation Pharmaceutical composition
DE3410732A1 (de) * 1984-03-23 1985-09-26 Hoechst Ag, 6230 Frankfurt Methode zur behandlung des glaukoms
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration
JPH05306296A (ja) * 1992-04-24 1993-11-19 Marino Forum 21 魚類由来ペプチドとその製法
WO1999036062A1 (en) * 1998-01-16 1999-07-22 Alcon Laboratories, Inc. Topical administration of angiotensin-converting enzyme inhibitors

Also Published As

Publication number Publication date
CZ20014516A3 (cs) 2002-05-15
HUP0201478A2 (hu) 2002-11-28
WO2000076499A3 (fr) 2001-05-17
MXPA01012907A (es) 2003-06-24
JP2003501461A (ja) 2003-01-14
MA26798A1 (fr) 2004-12-20
NO20016088L (no) 2002-02-12
AU6449000A (en) 2001-01-02
US7049340B1 (en) 2006-05-23
SI1185255T1 (sl) 2009-08-31
ATE424819T1 (de) 2009-03-15
SK18772001A3 (sk) 2002-04-04
ES2324200T3 (es) 2009-08-03
HUP0201478A3 (en) 2004-05-28
NO20016088D0 (no) 2001-12-13
EP1185255A2 (fr) 2002-03-13
WO2000076499A2 (fr) 2000-12-21
EP1185255B1 (fr) 2009-03-11
CA2376909A1 (fr) 2000-12-21
BR0011714A (pt) 2002-03-05
PL352365A1 (en) 2003-08-25
DE60041765D1 (de) 2009-04-23
DK1185255T3 (da) 2009-07-06

Similar Documents

Publication Publication Date Title
IL170685A0 (en) Protein conjugate
WO2003089033A8 (en) Implantable drug delivery system responsive to intra-cardiac pressure
WO2006082588A3 (en) Method and device for ophthalmic administration of active pharmaceutical ingredients
ATE493981T1 (de) Einmal tägliche dosierformen von trospium
TR200200620T2 (tr) Levosimendan farmasötik solüsyonları
TR200103665T2 (tr) Nöro ve -retino-koruyucu oftalmolojik ilaçlar
EP1643999B8 (en) Pyridoxamine for use in the treatment of diabetic nephropathy in type ii diabetes
EP1226822A3 (en) Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same
Froner et al. Injection of sodium hypochlorite by intravenous drug users
RU2000101091A (ru) Способ лечения дистрофических заболеваний сетчатки и зрительного нерва
WO2005102303A3 (en) Antiprostaglandins for the treatment of ocular pathologies
WO2002058532A3 (en) Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof
EP4245366A3 (en) Migalastat for treating fabry patients having renal impairment
ATE224727T1 (de) Faktor xiii zur behandlung von hautwunden
US9545409B2 (en) Use of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof in pharmaceutical compositions as a neuroretinal protector
Goldberg Comparison of tropical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J. Glaucoma 2001; 10: 414-22
WO2007036920A3 (en) Therapeutic use of polyanhydroglucronic acid
Ault US FDA advisers back new myopia aid.
Horowitz It's Not Just Athlete's Foot.
Stephan et al. Large scale study of the safety of prazosin Gastrointestinal Therapeutic System (GITS) in mild to moderate hypertension in everyday practice in France.
Strange Incontinence can be controlled.
RU94000179A (ru) Глазной гель
CY1110476T1 (el) Οφθαλμολογικα φαρμακα προστατευτικα του αμφιβληστροειδους τα οποια περιεχουν ραμιπριλη ή ραμιπριλατη
RU94024966A (ru) Средство для улучшения процессов микроциркуляции и коррекции иммуногемостатических нарушений при лечении глазных заболеваний
Roberts Antifibrinolytic agents in traumatic hemorrhage